Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Common Equity (2022 - 2025)

Historic Common Equity for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $340.7 million.

  • Entrada Therapeutics' Common Equity fell 1934.7% to $340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.7 million, marking a year-over-year decrease of 1934.7%. This contributed to the annual value of $428.7 million for FY2024, which is 7687.65% up from last year.
  • According to the latest figures from Q3 2025, Entrada Therapeutics' Common Equity is $340.7 million, which was down 1934.7% from $379.5 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Common Equity ranged from a high of $429.9 million in Q2 2024 and a low of $206.9 million during Q2 2023
  • Its 4-year average for Common Equity is $306.2 million, with a median of $269.4 million in 2024.
  • Per our database at Business Quant, Entrada Therapeutics' Common Equity soared by 10778.56% in 2024 and then plummeted by 1934.7% in 2025.
  • Entrada Therapeutics' Common Equity (Quarter) stood at $212.6 million in 2022, then rose by 14.02% to $242.4 million in 2023, then skyrocketed by 76.88% to $428.7 million in 2024, then dropped by 20.52% to $340.7 million in 2025.
  • Its last three reported values are $340.7 million in Q3 2025, $379.5 million for Q2 2025, and $417.3 million during Q1 2025.